CLVS Clovis Oncology Inc.

Newman Ferrara LLP Announces Corporate Governance Investigation of Clovis Oncology Inc.

NEW YORK--(BUSINESS WIRE)--

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Clovis Oncology Inc. (“Clovis” or the “Company”)(NASDAQ:CLVS) focusing on potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).

Clovis is a biopharmaceutical company headquartered in Boulder, Colorado. Despite the Company’s lack of revenue, low market capitalization, and increasing investment in research and development since it became a public company in 2011, the Board continues to make decisions, without shareholder approval, that significantly diminish shareholder value and do not benefit the Company. Based on this, it appears the Board lacks the ability to fairly assess and oversee the Company’s direction and leadership.

Current Clovis stockholders seeking more information on this matter are invited to contact Newman Ferrara attorneys Jeffrey Norton ([email protected]) or Roger Sachar, Jr. ([email protected]) to discuss this investigation and their rights.

Newman Ferrara maintains a multifaceted practice based in New York City with attorneys specializing in complex commercial and multi-party litigation, securities fraud and shareholder litigation, consumer protection, civil rights, and real estate. For more information, please visit the firm website at www.nfllp.com.

EN
30/11/2016

Underlying

CLVSClovis Oncology Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Clovis Oncology Inc.

 PRESS RELEASE
Free
CLVS Clovis Oncology...

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreem...

BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the “Debtors”) have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware (“Bankruptcy Court”) and will seek to sell their assets through a court supervised sales process. The Debtors have filed vario...

December 12, 2022 1 EN
 PRESS RELEASE
Free
CLVS Clovis Oncology...

Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (...

BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation titled, “TRITON3: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy in mCRPC Associated with Homologous Recombination Deficiency (HRD)” is being presented by Alan H. Bryce, MD, chair of the Division of Hematology and Medical Oncology at the Mayo Clinic and co-principal investigator of the TRITON3 trial during the session titled, “Novel C...

October 27, 2022 1 EN
 PRESS RELEASE
Free
CLVS Clovis Oncology...

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Ra...

BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286). Overall, in eleven patients treated in the first three dose cohorts, 177Lu-FAP-2286 demonstrated a manageable safety profile and enc...

October 17, 2022 1 EN
 PRESS RELEASE
Free
CLVS Clovis Oncology...

TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoin...

BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced positive top-line data from the Phase 3, open-label, multicenter, randomized TRITON3 trial demonstrating that Rubraca monotherapy treatment achieved the primary endpoint of significantly improved radiographic progression-free survival (rPFS) by independent radiology review (IRR) compared with the control group, which consisted of physician’s choice of docetaxel, abiraterone acetate, or enzalutamide. Benefit was observed in both primary efficacy analyses of patients with chemotherapy-naïve metastatic castrati...

October 3, 2022 1 EN
 PRESS RELEASE
Free
CLVS Clovis Oncology...

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agr...

BOULDER, Colo. & PETACH TIKVA, Israel--(BUSINESS WIRE)-- and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopia’s lutetium-177 (177Lu) n.c.a. for use in the clinical development of FAP-2286, Clovis’ fibroblast activation protein (FAP)-targeting therapeutic candidate. FAP-2286 is the first peptide-targeted radionuclide therapeutic (PTRT) candidate directed against fibroblast activation protein undergoing clinical testing and is currently being investigated in the Phase 1/2 LuMIERE study for patients with advanc...

September 21, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch